FOXP3 and neoplasm: This suggests that the levels of FOXP3 expression, as for SPARC, in the patient's primary tumour may play an important prognostic role that could assist in distinguishing between stage II cancers that would, and would not, benefit from post-operative adjuvant chemotherapy.